CONGRESSES

GUT MICROBE

The Chronic Liver Disease Foundation provides education to the medical community
concerning a disease that affects an estimated 40 million people in the United
States.

The most common types of CLD in the United States include nonalcoholic fatty liver
disease, nonalcoholic steatohepatitis, chronic hepatitis C, alcoholic liver disease,
chronic hepatitis B, and hemochromatosis.

For all age groups, CLD was the 12th leading cause of death in the year 2000,
accounting for more than 25,000 deaths. In the 45 to 54 age group, CLD and cirrhosis
were the 4th leading cause of death in males, and the 6th leading cause of death in
females.

More than 17,000 patients are currently on the liver transplant waiting list, yet just
over 5000 patients receive liver transplants each year.

New therapies continue to evolve in the treatment of CLD. New molecular testing
techniques aid in the detection and therapeutic monitoring of liver disease.
Recombinant vaccines have been developed for 2 common types of hepatitis. And, in
those cases where liver disease has progressed to a point where treatment is no
longer effective, liver transplant has become a more viable option, in most instances,
than it was just a decade ago.

Please visit our site!

Jan

5

NASH-TAG Conference
Learn from world-changing thinkers and innovators in NASH and Fibrosis at NASH-TAG 2017. The NASH-TAG Conference is designed to bring together clinicians and researchers in academia and the pharmaceutical industry for a focused interactive educational update highlighting the most relevant advances and challenges in the diagnosis and therapy of NASH and liver fibrosis.

Mar

25

GALA Arlington
Next for GALA 2017 is Arlington, TX. Come see this comprehensive educational update in chronic liver and
Gi news.

STAY CONNECTED